


**ABSTRACT**

This invention provides a compound of the formula (I):



5

(I)

or the pharmaceutically acceptable salts thereof, wherein Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> are independently selected from N, CH, etc.; R<sup>1</sup> is H, C<sub>1-8</sub> alkyl, etc.; Q<sup>1</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, etc.; A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; B is C<sub>1-6</sub> alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R<sup>2</sup> is H, C<sub>1-4</sub> alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.; L is halo, C<sub>1-4</sub> alkyl, etc.; m is 0, 1 or 2; R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; R<sup>5</sup> is H, C<sub>1-4</sub> alkyl, etc.; Q<sup>2</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc. These compounds are useful for the treatment of medical conditions mediated by prostaglamndin such as pain, fever or inflammation, etc. This invention also provides a pharmaceutical composition comprising the above compound.

15